CND Life Sciences
CND Life Sciences is a Scottsdale-based medical technology company that operates a CLIA-certified laboratory providing the Syn-One Test, a skin biopsy-based diagnostic for detecting phosphorylated alpha-synuclein to diagnose Parkinson's disease and related synucleinopathies for neurologists and biopharmaceutical sponsors.
- Company typePrivate
- Founded2020
- HeadquartersScottsdale, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What CND Life Sciences does
CND Life Sciences is a Scottsdale, Arizona-based medical technology company founded in 2020 that has developed the Syn-One Test, the first commercially available skin-based diagnostic for detecting phosphorylated alpha-synuclein in cutaneous nerve fibers to aid in the diagnosis of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The test uses a minimally invasive skin biopsy analyzed via immunofluorescence in the company's CLIA-certified, CAP-accredited laboratory, reporting >95% sensitivity and specificity, and has been ordered nearly 50,000 times in the U.S. by 3,500+ neurologists. The company supplements its clinical diagnostic franchise with a Small-Fiber Dx test for peripheral neuropathy and a Syn-One Biomarker Services offering that supplies biopharmaceutical companies with biomarker analysis for Parkinson's disease clinical trials, including the ABLi Therapeutics Phase 2 risvodetinib study.
The company generates revenue primarily through per-test laboratory diagnostic services paid by Medicare and other payers, supplemented by contract research revenue from biopharma biomarker services. Distribution is direct-to-clinician via a kit ordering system, with patient self-pay available as a secondary channel, and direct enterprise engagement with pharmaceutical trial sponsors. The business operates from CLIA-certified laboratory facilities in Scottsdale and Boston, with additional offices in Atlanta and Brookline, and holds state-level clinical laboratory licenses in New York, California, Maryland, Pennsylvania, and Rhode Island. CND is venture-backed with cumulative equity exceeding $20M led by a $13.5M Series A in May 2025 with Labcorp, supplemented by approximately $8.4M in NIH grants, and is led by physician-scientist co-founders from Harvard Medical School, Beth Israel Deaconess Medical Center, and HonorHealth, with a commercial organization in active buildout under a newly hired SVP, Commercial.
CND Life Sciences firmographics
Firmographics- Name
- CND Life Sciences
- Legal name
- CND Life Sciences, Inc.
- Website
- https://cndlifesciences.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- CND Life Sciences is a Scottsdale-based medical technology company that operates a CLIA-certified laboratory providing the Syn-One Test, a skin biopsy-based diagnostic for detecting phosphorylated alpha-synuclein to diagnose Parkinson's disease and related synucleinopathies for neurologists and biopharmaceutical sponsors.
- Ownership category
- akta.pro rank
CND Life Sciences industry classification
Industry- Product category
- Neurological Diagnostic Laboratory Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurodiagnostic Centers (EEG/EMG/NCS) (HLAFAKAK)
- akta.pro secondary industries
- Movement Disorders (Parkinson’s, Tremor, Dystonia) (HLAKAIAC), Neurogenetics & Rare Neurologic Diseases (HLAKAIAO)
Keywords
Where CND Life Sciences is headquartered
LocationHeadquarters
- HQ city
- Scottsdale
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
CND Life Sciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Clinical Diagnostic Testing: CND provides laboratory testing services through its CLIA-certified and CAP-accredited laboratory. Clinicians order skin biopsy test kits, collect samples from patients, and send them to CND for analysis. Results are reported back to clinicians to support diagnostic decision-making. Revenue is generated per test performed, with Medicare coverage established and commercial payer relationships being developed.
- Biomarker Services for Biopharma: CND offers biomarker analysis services to pharmaceutical companies conducting clinical trials for neurodegenerative disease therapeutics. The company's Syn-One test is used as a biomarker endpoint in drug trials, such as the ABLi Therapeutics Phase 2 trial for risvodetinib, generating contract research revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Laboratory testing services for neurodegenerative disease diagnosis |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
CND Life Sciences product offering
Product offeringCore offering
CND Life Sciences operates a CLIA-certified, CAP-accredited diagnostic laboratory that provides the Syn-One Test, a skin biopsy-based assay detecting phosphorylated alpha-synuclein in cutaneous nerve fibers to help clinicians diagnose Parkinson's disease and related synucleinopathies, plus Small-Fiber Dx for peripheral neuropathy assessment. The company also delivers Syn-One Biomarker Services to biopharmaceutical companies for use as endpoints and patient stratification tools in neurodegenerative disease clinical trials, leveraging its NerValence AI-assisted digital pathology platform co-developed with Visiopharm.
Product overview
CND Life Sciences offers a portfolio of skin-based neurodiagnostic tests and biomarker services. The flagship product is the Syn-One Test, the first commercially available skin-based test to detect phosphorylated alpha-synuclein in cutaneous nerve fibers to aid diagnosis of Parkinson's disease and other synucleinopathies. The company also provides Small-Fiber Dx for evaluating small fiber neuropathy when nerve conduction studies are normal. Through its Biopharma division, CND offers Syn-One Biomarker Services for pharmaceutical clinical trials, utilizing its AI-assisted digital pathology tool NerValence (developed with Visiopharm) to analyze skin biopsy samples.
Differentiator
Problem solved
Functional benefit
Brands
- Syn-One Test: The first commercially available skin-based test to help clinicians diagnose Parkinson's disease and related disorders by detecting phosphorylated alpha-synuclein in skin biopsies.
- Small-Fiber Dx
- Syn-One Biomarker Services
Products and services
- Syn-One Test The first commercially available skin-based diagnostic test that uses a minimally invasive skin biopsy and immunofluorescence to detect phosphorylated alpha-synuclein (P-SYN) in cutaneous nerve fibers, helping clinicians diagnose Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and related synucleinopathies. The test has >95% sensitivity and specificity, has been ordered nearly 50,000 times in the U.S., is covered by Medicare, and is used by 3,500+ U.S. neurologists.
- Small-Fiber Dx A diagnostic test for evaluating small fiber neuropathy when standard nerve conduction studies are normal but patients may still have isolated small fiber neuropathy. The test assesses small nerve fiber dysfunction, including intra-epidermal nerve fiber density, to support diagnosis of peripheral neuropathy conditions.
- Syn-One Biomarker Services Biomarker analysis services offered to biopharmaceutical companies for use in clinical trials, enabling measurement of phosphorylated alpha-synuclein in skin biopsies as trial endpoints or patient stratification tools. Leverages the proprietary NerValence AI-assisted digital pathology tool (developed in collaboration with Visiopharm) for enhanced precision and consistency.
Quantifiable outcome
- Skin biopsy findings influenced patient management in 71.2% of cases (52/73)
- +4 more outcomes
Companies that use CND Life Sciences
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles2 records
CND Life Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
CND Life Sciences partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- ABLi TherapeuticscoreCND's Syn-One Biomarker Services were used in ABLi Therapeutics' Phase 2 clinical trial for their Parkinson's disease drug candidate risvodetinib. Analysis of 36 subjects showed a reduction in phosphorylated alpha-synuclein deposition over 12 weeks, marking the first-ever measure of its kind to demonstrate a possible treatment effect on intra-neuronal synuclein deposition in a Parkinson's disease drug trial.
- Visiopharm (Denmark)coreCND collaborated with Denmark-based Visiopharm to develop NerValence, an AI-assisted digital pathology tool used to analyze skin biopsy samples with enhanced precision and consistency.
- Indie StudiosminorIndie Studios provides co-working office space for CND's Atlanta location at 190 Ottley Drive NE, Suite J, Atlanta, GA 30324-3925.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
CND Life Sciences competitors and assessment
Company assessmentBroad incumbents
- Roche Diagnostics: Roche develops Elecsys CSF-based biomarker assays for Alzheimer's and is developing alpha-synuclein diagnostic assays through Roche Tissue Diagnostics. A broad incumbent in CNS biomarker diagnostics with global scale and an active pharmaceutical companion diagnostic pipeline.
- Labcorp: Labcorp is a leading global clinical laboratory services company and CND's lead Series A investor. Operates extensive neurological and neurodegenerative disease testing menus and could be both a channel partner and a competitor if it internalizes similar P-SYN testing capabilities.
- Quanterix: Quanterix develops the Simoa single-molecule array platform for ultra-sensitive biomarker detection, used in neurodegenerative disease research and diagnostics. Comparable to CND as an enabling ultra-sensitive biomarker detection platform serving both research and clinical neurodiagnostic applications.
- Quest Diagnostics: Quest Diagnostics is one of the largest U.S. clinical laboratory networks, offering neurological and genetic testing services through its Athena Diagnostics specialty neurology division. Represents both an established competitor in the neurology diagnostics market and a potential strategic acquirer.
- ARUP Laboratories: ARUP Laboratories is a national reference laboratory affiliated with the University of Utah, offering specialized neurological and neurogenetic testing panels. Comparable to CND as a specialty neurodiagnostic reference lab serving academic medical centers and clinicians nationwide.
- Mayo Clinic Laboratories: Mayo Clinic Laboratories operates a major reference laboratory offering extensive neurological and neurodegenerative disease testing panels, including alpha-synuclein and related biomarker assays. Established broad incumbent in the same clinical neurodiagnostic market CND serves, with significantly greater scale and payer relationships.
Direct peers
- Amprion: Amprion develops SAAmplify, a CSF-based alpha-synuclein aggregation assay (PMCA/RT-QuIC technology) for diagnosing synucleinopathies. Direct competitor to CND's Syn-One, addressing the same clinical question of pathological synuclein detection but using cerebrospinal fluid rather than skin biopsies.
- C2N Diagnostics: C2N Diagnostics offers PrecivityAD, a blood-based biomarker test for Alzheimer's disease pathology, and is expanding into neurodegenerative disease diagnostics via mass spectrometry-based assays. Highly comparable to CND's model of objective blood/tissue-based biomarker diagnostics for neurodegenerative disease serving neurologists and biopharma.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
CND Life Sciences social profiles
Digital presenceCND Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
CND Life Sciences leadership team
Management profileNumber of profiles
Profiles17 records
CND Life Sciences funding detail
Funding detailFunding overview
Funding rounds13 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CND Life Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CND Life Sciences
What does CND Life Sciences do?
CND Life Sciences operates a CLIA-certified, CAP-accredited diagnostic laboratory that provides the Syn-One Test, a skin biopsy-based assay detecting phosphorylated alpha-synuclein in cutaneous nerve fibers to help clinicians diagnose Parkinson's disease and related synucleinopathies, plus Small-Fiber Dx for peripheral neuropathy assessment. The company also delivers Syn-One Biomarker Services to biopharmaceutical companies for use as endpoints and patient stratification tools in neurodegenerative disease clinical trials, leveraging its NerValence AI-assisted digital pathology platform co-developed with Visiopharm.
Is CND Life Sciences a public or private company?
CND Life Sciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was CND Life Sciences founded?
CND Life Sciences was founded in 2020. It employs 101 to 250 people.
Where is CND Life Sciences based?
CND Life Sciences is headquartered in Scottsdale, United States, in the North America region.
How does CND Life Sciences make money?
Two revenue lines are on record. Clinical Diagnostic Testing is the primary driver. The others are biomarker Services for Biopharma.
Who are CND Life Sciences's main competitors?
Broad incumbents on record are Roche Diagnostics, Labcorp, Quanterix, Quest Diagnostics, ARUP Laboratories and Mayo Clinic Laboratories. Direct peers are Amprion and C2N Diagnostics.
Does CND Life Sciences have an API?
No public API is recorded for CND Life Sciences.
What industry is CND Life Sciences in?
CND Life Sciences's product category is Neurological Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAFAKAK, Neurodiagnostic Centers (EEG/EMG/NCS), with a secondary code of HLAKAIAC, Movement Disorders (Parkinson’s, Tremor, Dystonia). Its NAICS code is 621511 and its SIC code is 8071.